These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 16265875)

  • 1. Obstacles and opportunities in the clinical development of targeted therapeutics.
    Dy GK; Adjei AA
    Prog Drug Res; 2005; 63():19-41. PubMed ID: 16265875
    [No Abstract]   [Full Text] [Related]  

  • 2. Bypassing phase 1 trials in the cancer drug development paradigm: generally unwise and potentially dangerous.
    Markman M
    Cancer; 2010 Nov; 116(22):5116-8. PubMed ID: 20665504
    [No Abstract]   [Full Text] [Related]  

  • 3. Next generation oncology drug development: opportunities and challenges.
    Gutierrez ME; Kummar S; Giaccone G
    Nat Rev Clin Oncol; 2009 May; 6(5):259-65. PubMed ID: 19390552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of farnesyltransferase: a rational approach to cancer chemotherapy?
    Bell IM
    J Med Chem; 2004 Apr; 47(8):1869-78. PubMed ID: 15055985
    [No Abstract]   [Full Text] [Related]  

  • 5. Developmental therapeutics in childhood cancer. A perspective from the Children's Oncology Group and the US Food and Drug Administration.
    Bernstein ML; Reaman GH; Hirschfeld S
    Hematol Oncol Clin North Am; 2001 Aug; 15(4):631-55. PubMed ID: 11676277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of elderly patients with antineoplastic chemotherapy.
    Tirelli U; Monfardini S
    J Clin Oncol; 1995 May; 13(5):1282-3. PubMed ID: 7738634
    [No Abstract]   [Full Text] [Related]  

  • 7. Cancer drugs. Smart weapons prove tough to design.
    Couzin J
    Science; 2002 Oct; 298(5593):522-5. PubMed ID: 12386312
    [No Abstract]   [Full Text] [Related]  

  • 8. Broadening Eligibility Criteria for Oncology Clinical Trials: Current Advances and Future Directions.
    Rahman NA; Ison G; Beaver JA
    Clin Pharmacol Ther; 2020 Sep; 108(3):419-421. PubMed ID: 32640034
    [No Abstract]   [Full Text] [Related]  

  • 9. [Mono-polychemotherapeutic treatment? The opportunities and limits].
    Carreca I; Dispenza J; Agueli R; Cucciarrè S
    Minerva Med; 1999; 90(7-8):203-4. PubMed ID: 10719418
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacodynamic endpoints as clinical trial objectives to answer important questions in oncology drug development.
    Parchment RE; Doroshow JH
    Semin Oncol; 2016 Aug; 43(4):514-25. PubMed ID: 27663483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reanalysis of cancer drugs: old drugs, new tricks.
    Vande Woude GF; Kelloff GJ; Ruddon RW; Koo HM; Sigman CC; Barrett JC; Day RW; Dicker AP; Kerbel RS; Parkinson DR; Slichenmyer WJ
    Clin Cancer Res; 2004 Jun; 10(11):3897-907. PubMed ID: 15173099
    [No Abstract]   [Full Text] [Related]  

  • 12. The cancer stem cell gamble.
    Kaiser J
    Science; 2015 Jan; 347(6219):226-9. PubMed ID: 25593170
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical trials referral resource. Clinical trials using edatrexate.
    Cheson BD; Sorenson JM; Phillips PH
    Oncology (Williston Park); 1993 Jul; 7(7):33-4. PubMed ID: 8347459
    [No Abstract]   [Full Text] [Related]  

  • 14. Opportunities and challenges in the development of experimental drug combinations for cancer.
    Humphrey RW; Brockway-Lunardi LM; Bonk DT; Dohoney KM; Doroshow JH; Meech SJ; Ratain MJ; Topalian SL; Pardoll DM
    J Natl Cancer Inst; 2011 Aug; 103(16):1222-6. PubMed ID: 21765011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracavitary chemotherapy.
    Markman M
    Curr Probl Cancer; 1986 Aug; 10(8):401-37. PubMed ID: 2427278
    [No Abstract]   [Full Text] [Related]  

  • 16. Medical oncology in the 1990s.
    Braverman AS
    Lancet; 1991 Apr; 337(8746):901-2. PubMed ID: 1672980
    [No Abstract]   [Full Text] [Related]  

  • 17. Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities.
    Venkatakrishnan K; Friberg LE; Ouellet D; Mettetal JT; Stein A; Trocóniz IF; Bruno R; Mehrotra N; Gobburu J; Mould DR
    Clin Pharmacol Ther; 2015 Jan; 97(1):37-54. PubMed ID: 25670382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thinking Systematically About the Off-Label Use of Cancer Drugs and Combinations for Patients Who Have Exhausted Proven Therapies.
    Mailankody S; Prasad V
    Oncologist; 2016 Sep; 21(9):1031-2. PubMed ID: 27401893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using "rationally designed drugs" rationally.
    Brugarolas J; Clark JW; Chabner B
    Lancet; 2003 May; 361(9371):1758-9. PubMed ID: 12781531
    [No Abstract]   [Full Text] [Related]  

  • 20. [Clinical evaluation of glyciphosphoramide used alone and in combination with other drugs].
    Wang ZY
    Zhonghua Zhong Liu Za Zhi; 1984 Sep; 6(5):379-81. PubMed ID: 6398774
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.